Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358514 | 0.88 | SYK (0.55) | LMNASYKIRAK4SMN1; SMN2IRAK1 | |
| SCHEMBL19265812 | 0.88 | PTK2 (0.50) | ALDH1A1LMNASYKIRAK4SMN1; SMN2 | |
| SCHEMBL19677062 | 0.88 | PTK2 (0.50) | ALDH1A1LMNASYKIRAK4SMN1; SMN2 | |
| SCHEMBL359125 | 0.80 | SYK (0.56) | SYKIRAK4IRAK1 | |
| SCHEMBL359849 | 0.79 | SYK (0.62) | SYKIRAK4IRAK1 | |
| SCHEMBL15093593 | 0.78 | SYK (0.61) | ALDH1A1SYKIRAK4SMN1; SMN2IRAK1 | |
| SCHEMBL1682820 | 0.78 | PTK2 (0.50) | PTK2 | |
| SCHEMBL19265894 | 0.77 | IRAK4 (0.52) | LMNASYKIRAK4SMN1; SMN2IRAK1 | |
| SCHEMBL358463 | 0.77 | SYK (0.65) | SYKIRAK4PTK2IRAK1 | |
| SCHEMBL358573 | 0.77 | SYK (0.65) | SYKIRAK4PTK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885LMNA 2020/4885SYK 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.